|
01 April 2009
Patients in need of visual corrections whose vision is not affected by existing high-order aberrations (HOAs) may have an alternative to wavefront treatment using an aberration-free method.
|
25 February 2009
Insights gained from research into keratoconus using extremely intense x-rays could refine laser surgeries, including LASIK, and may one day even lead to the development of an artificial cornea, according to researchers at Cardiff University, UK.
|
25 February 2009
A trial of electronic spectacles with dynamic focusing lenses has begun enrolling its first wearers, according to an announcement from the spectacles' manufacturer, PixelOptics Inc.
|
18 February 2009
Patients with nystagmus who posture their head to compensate for the condition tend to suffer restricted neck movements, concluded a study published in the February issue of Eye.
|
18 February 2009
The Gebauer SL Keratome, a sterile single-use instrument for performing Epi-LASIK and LASIK surgeries, has received FDA clearance and can now be distributed for sale in the US.
|
11 February 2009
Prolacria (diquafosol tetrasodium ophthalmic solution) 2% has entered a Phase III trial for the treatment of dry eye disease, according to an announcement from the solution's developer, Inspire Pharmaceuticals, Inc.
|
11 February 2009
Ophthalmology Times Europe, in conjunction with Carl Zeiss Meditec, is to host a free online seminar aimed specifically at cataract and refractive surgeons, explaining how to integrate the Acri.LISA multifocal intraocular lens (IOL) into practice.
|
11 February 2009
Human corneal epithelial cells, grown in the lab, are being used in preclinical trials, evaluating if it is possible to enhance the photorefractive keratectomy (PRK) procedure, according to a statement from the trial organizer, International Stem Cell Corporation (ISCO).
|
21 January 2009
The Investigational New Drug (IND) application for NVC-422, a molecule under investigation by NovaBay Pharmaceuticals for the treatment of eye infections, has been cleared by the FDA, triggering a development milestone payment from Alcon to NovaBay of $1 million.
|
|
